Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/24 cls
BioSante (BPA) Oppenheimer Kevin DeGeeter New Buy 1% $5.86
DeGeeter set a $9 target. He believes BPA's LibiGel testosterone to treat hypoactive sexual desire disorder (HSDD) has potential sales of >$500M, which may be monetized over the next 12-18 months through a commercial partnership or sale of the company.

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers